PMID-33076834 – Entecavir Plus Thymosin Alpha-1 for HBV Cirrhosis: Meta-Analysis
Peng D et al. "The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis," BMC Gastroenterology, 2020;20(1):348. doi:10.1186/s12876-020-01477-8
Quick Reference
| Property | Value |
|---|---|
| PMID | 33076834 |
| DOI | 10.1186/s12876-020-01477-8 |
| Year | 2020 |
| Journal | BMC Gastroenterology |
| Study Type | Systematic Review / Meta-analysis |
| Evidence Level | I |
| Sample | 7 RCTs, n=1,144 patients with HBV-related cirrhosis |
| Peptide(s) Studied | Thymosin Alpha-1 |
Key Findings
- Adding Tα1 to entecavir produced higher clinical response rates at 24 weeks vs. entecavir alone
- Lower adverse reaction rates in the combination group
- Benefits attenuated at 48-52 weeks (sustained response less clear)
- Combination therapy improved liver function markers in the short term
Study Design
Systematic review and meta-analysis of 7 RCTs (1,144 patients) comparing entecavir + thymosin alpha-1 combination vs. entecavir monotherapy for HBV-related cirrhosis. PRISMA-compliant. Multiple timepoint analyses.
Limitations
- All included RCTs from China; generalizability uncertain
- Attenuation of benefit at longer follow-up raises questions about sustained efficacy
- Variable quality of included RCTs
Clinical Relevance
Directly supports ZADAXIN's approved HBV indication. The combination approach (antiviral + immunomodulator) is the standard therapeutic strategy for chronic HBV in countries where thymosin alpha-1 is approved. The attenuation at 48+ weeks suggests the immune boost may be time-limited.
Related
#research #meta-analysis #evidence-level-I